Science Immunology Submission Process

Science Immunology process problems usually begin before the portal opens. The package should already answer four questions.

If those answers are weak, the process will not fix them. It will expose them.

Prepare the package before starting the online form. AAAS systems are manageable when the files are stable and slow when the manuscript is still changing.

You should have:

• manuscript file with title page, one-sentence summary, abstract, main text, references, figure legends, and declarations aligned
• separate figure files with readable panels and consistent labels
• supplementary materials file with methods, supporting figures, tables, and extended data
• cover letter addressed to the Science Immunology editorial team
• competing-interest, funding, author-contribution, and data-availability statements
• ethics approval and consent language for human, animal, clinical, or patient-derived work
• code, sequencing, flow-cytometry, single-cell, imaging, or structural-data repository links where applicable
• suggested reviewers spanning immunology mechanism, disease/model system, and broad Science-family perspective

This is not just administrative. A weak one-sentence summary, a vague data statement, or suggested reviewers from one narrow disease community gives the editor a weaker first signal before the main text is judged.

Science Immunology submissions go through the AAAS Science Content Tracking System. During upload, the corresponding author enters manuscript metadata, author details, article type, files, suggested reviewers, disclosures, and cover letter.

The portal URL matters because it fixes the workflow shape: https://cts.sciencemag.org. The Science Content Tracking System is the AAAS Manuscript Tracking System for Science-family journals, so the upload becomes an editor-readable package rather than a file transfer. In our Science Immunology process reviews, the upload fields often reveal whether the manuscript is controlled before the editor reads the science.

A precise article type, complete disclosures, consistent author metadata, clean figures, a strong one-sentence summary, and a non-generic cover letter make the first editorial read faster. Weak uploads force the editor to decide whether the package is a Science Immunology submission or an unfinished immunology manuscript trying to borrow AAAS prestige.

The practical upload sequence is:

1. create or enter the AAAS CTS account
2. choose the article type, usually Research Article, Report, Review, or Perspective
3. enter title, one-sentence summary, abstract, keywords, authors, affiliations, and corresponding-author details
4. upload manuscript, figures, supplementary materials, and cover letter
5. complete disclosures, funding, ethics, consent, data availability, and code availability fields
6. add suggested reviewers and any opposed reviewers with justification
7. review the generated submission package carefully before final submission

Do not skip the generated-package check. Figure order, missing legends, broken symbols, author-order mistakes, or supplementary-material omissions are easiest to catch before the manuscript becomes an editorial file.

Use these as planning ranges, not promises. AAAS does not publish a guaranteed decision clock for every Science Immunology manuscript, and reviewer availability changes by topic. The useful signal is which gate the manuscript is likely facing. For manuscripts that clear the editor's first screen, expect a first decision in about 6 to 12 weeks, with complex reviewer searches sometimes extending the first decision toward 12 to 16 weeks.

The calibrated range is therefore: fast editorial decisions can arrive in the first 1 to 3 weeks, externally reviewed papers often need about 6 to 12 weeks for a first decision, and hard reviewer searches or added reviewers can push the first reviewed decision toward 12 to 16 weeks. If the paper is still quiet after a month, that does not automatically mean trouble; it often means reviewer recruitment or report waiting.

AAAS's journal-specific process feature to remember is anonymous peer review plus Science-family transfer and routing, not transparent peer review or portable peer review in the eLife sense. A Science Immunology decision may point authors toward Science, Science Advances, Science Translational Medicine, or a narrower immunology venue depending on the real manuscript center. Treat transfer as a fit signal, not an automatic path. Accept it only if the suggested journal owns the actual manuscript: broad Science-family significance, translational medicine, specialist immunology, or soundness-led scope.

After submission, AAAS intake checks whether the package is complete enough to move forward. This is not the scientific review, but it can delay the manuscript.

Common intake delays:

• one-sentence summary is missing, too long, or not aligned with the abstract
• competing-interest or funding statements are incomplete
• data or code availability is vague for sequencing, single-cell, flow, imaging, or computational work
• ethics approval or consent language is unclear for human or animal work
• supplementary materials are missing, corrupted, or inconsistent with the main text
• figure files are low resolution or inconsistent with legends
• author metadata differs between the form and manuscript
• suggested reviewers are too close to the authors or too narrow in subfield

Fix these before upload. Administrative returns are not fatal, but they make the process slower and signal that the package was not fully controlled.

Once the file is administratively complete, it moves to editorial handling. This is where Science Immunology decides whether the manuscript belongs in the AAAS immunology specialist slot.

The editor usually reads the title, one-sentence summary, abstract, cover letter, first figures, and scope signals first. The question is not "is this immunology?" It is "is this a Science Immunology paper?"

Strong process signals:

• the one-sentence summary states the immunology advance clearly
• the abstract connects mechanism to broad immunology consequence
• the first figures show causal or functional evidence, not only phenotype
• the cover letter explains why Science Immunology owns the manuscript
• data, methods, and supplementary materials can survive reviewer scrutiny

Weak process signals:

• the manuscript is a narrow disease-system story with generic Science-family language
• the first figure is descriptive phenotype before mechanism
• validation rests on one model, one cohort, one assay, or one perturbation
• the translational or clinical relevance is promised but not tested
• the cover letter argues prestige rather than immunology significance

This is why the submission-process page is separate from the submission-guide page. The guide can help assemble files. The process is about how the editor reads the assembled file.

Science Immunology triage is an immunology-significance and mechanism screen. Manuscripts that look narrow, under-validated, or weakly Science-family can leave the process before peer review.

Methodology note: this page was created from official AAAS source checks, sibling-page overlap checks, and Manusights submission analysis of immunology manuscripts. In our analysis of Science Immunology submission packages, the fastest triage failures are consistent. We evaluate the same components an editor sees early: one-sentence summary, abstract, first figure, cover letter, validation figure, methods/supplement, data package, and suggested-reviewer field. The strongest Science Immunology packages make the immunology advance visible before the editor reaches the full results. The weakest packages ask the editor to infer broad significance from a local disease model, cell subset, or assay.

Specialist immunology without broad Science Immunology consequence. This specific failure pattern is the fastest way for a Science Immunology process to end early. A T-cell, B-cell, innate, mucosal, vaccine, tumor-immunology, or autoimmunity result can be technically strong and still read too local. Editors actually look for why immunologists outside the immediate subfield should care before they spend reviewer capacity.

Check whether your Science Immunology abstract reads as broad immunology or narrow subfield work →.

Phenotype before mechanism. A strong immune phenotype is vulnerable when the causal pathway remains inferred. A stronger package shows perturbation, rescue or orthogonal validation, second model support, and mechanistic specificity. Manusights internal analysis treats this as a submission-process issue because it changes whether the editor recruits reviewers or returns the paper before review.

Check whether your Science Immunology validation package is broad enough →.

Wrong Science-family route. Some manuscripts are better suited to Science, Science Advances, Science Translational Medicine, Nature Immunology, Immunity, JEM, JCI, or Cell Host & Microbe. Science Immunology owns specialist top-tier immunology. A general-science claim, translational-medicine center, or host-microbe center should route differently.

Check whether your Science Immunology fit argument matches the evidence →.

The one-sentence summary hides the advance. If the summary names a model system but not the immunology contribution, the first read loses force. The same problem appears when the cover letter says "broad significance" but the first figure shows a local phenotype.

Our analysis of Science Immunology submission packages treats triage as a document-level test. The manuscript component that fails first is usually visible before peer review: one-sentence summary, abstract claim, first figure, validation breadth, methods/supplement package, or target-journal premise.

The practical pattern is specific to Science Immunology. A paper can have a valid immunology dataset and still enter the process weakly if the first screen sees a disease model before an immunology advance. We look for whether the one-sentence summary names the immunological finding, the abstract states the mechanism, the first figure makes the immune question visible, and the validation evidence is not hidden late.

We also inspect the cover letter for a journal-specific sentence: why this manuscript belongs in Science Immunology rather than Science, Science Advances, Science Translational Medicine, Nature Immunology, Immunity, Journal of Experimental Medicine, JCI, or Cell Host & Microbe. If that sentence is vague, the process often becomes slower because the editor has to reconstruct the target fit.

The reviewer-count expectation is also practical. If the manuscript goes out, expect two to three reviewers with different jobs: one immunology-mechanism reviewer, one disease or model-system reviewer, and sometimes one computational, translational, clinical, vaccine, or single-cell reviewer. The review tells you whether your paper passes the same process screen editors look for before reviewer invitation. A paid Manusights review applies that same division before submission: mechanism, validation, journal fit, and reviewer-risk checks. Paid reviews include the 60-day money-back guarantee, and Manusights does not train models on submitted manuscripts. We do not train on submitted manuscripts.

If the manuscript clears triage, the editor invites reviewers. The likely reviewer mix depends on the manuscript center: immune mechanism, disease model, vaccine, tumor immunology, infection, autoimmunity, mucosal biology, computational immunology, clinical samples, or method.

Reviewer assignment can slow when:

• the topic is narrow and qualified reviewers are conflicted
• suggested reviewers are too close to the authors
• the paper spans immunology plus a specialist method
• the manuscript needs both mechanistic and clinical review
• the cover letter does not clarify the core contribution

Once reviewers agree, they usually test the same issues the editor screened for: immunology advance, mechanism, validation, controls, model choice, statistics, data availability, broad relevance, and whether the claim is proportionate.

The first decision after review is usually not a clean accept. For a promising Science Immunology manuscript, expect major revision or detailed reviewer feedback around validation and claim strength.

The best revision responses do not merely answer reviewer comments. They show that the manuscript now supports the immunology claim more directly than the submitted version did.

Do not interpret every quiet week as bad news. The stronger signal is which phase the manuscript is likely in. Early quiet often means editorial or reviewer recruitment. Later quiet usually means reports or decision synthesis.